Kuzovunywa ukulingisa kokuqala okungu-200!Imikhiqizo eshisayo yokulingisa yezinkampani ezinkulu yadalulwa.

1.Ukunwetshwa kwebhizinisi: Ukutholwa kabusha kwezokwelapha kwe-Yuyue, ukubanjwa okungu-100%.

Muva nje, uhlelo lokusebenza lokuhlola ibhizinisi lubonisa ukuthi i-Jiangsu Lerun contact lens Co., Ltd. ibe nezinguquko zezimboni nezentengiso, abanikazi bamasheya bokuqala i-Jiangsu Hongyi Garden Construction Engineering Co., Ltd. kanye ne-Danyang xintongqiu optical glasses Co., Ltd. bahoxile, futhi umninimasheya omusha u-Yuyue medical (002223) uphethe u-100%.Kuhle ukusho ukuthi kusukela ngo-2019, u-Yuyue wasebenzisa cishe ama-yuan ayizigidi ezingu-80 ukuze athole amabhizinisi amabili emishini yamehlo.

2.Ngomhla zingama-24 kuNhlaba, iwebhusayithi esemthethweni ye-Zhejiang Pharmaceutical Machinery Procurement Center yakhipha isaziso mayelana nezinga lenani lempahla yokugcina izidakamizwa ngo-2021, futhi ulwazi olufanele lwemikhiqizo ephezulu engama-200 lwamenyezelwa ngokusemthethweni.I-Top10 ibigcwele izinkampani ezikhiqiza imithi yamazwe ngamazwe, kanye namaphilisi e-clopidogrel bisulfate avela e-China Stone Pharmaceutical Group nase-Europe Italy Pharmaceutical Co., Ltd., okuyinkampani yasekhaya eyenza imithi, ephethe i-Top11.

3.Ngaphansi kochungechunge lwezinqubomgomo, imithi emisha yasekhaya ingenise isikhathi sokuvuna esikhulu, futhi amabhizinisi emithi nawo angenile esikhathini sokushintshana kwempumelelo.Ngokwedatha ye-micnet, kusukela ngo-2011, cishe imithi emisha engu-90 yekilasi 1 yasekhaya (okuhlanganisa isigaba 1 no-1.1, ngaphandle kwemijovo yokugoma, efanayo ngezansi) igunyaziwe ukuthi ifakwe ohlwini, futhi izinkampani zemithi eziyi-15 zigunyaze izinhlobo ezi-2 noma ngaphezulu.Izinzuzo zekhemisi ezinkulu zendabuko zivelele, futhi i-Hengrui isendaweni yokuqala.Ngemuva kwe-hausen, i-head biotech ayizimisele ukuqedwa, futhi i-Baiji Shenzhou, i-Hehuang yezemithi neyokuthakasela i- zaiding iboshelwe endaweni yesithathu.

4.I-Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., inkampani engaphansi kwe-Guangzhou Pharmaceutical Group, okungelinye lamabhizinisi aphezulu angama-500 emhlabeni, imemezele ngobusuku bangoMeyi 30 ukuthi i-Baiyunshan Pharmaceutical General Factory ithole incwadi evela e-US FDA (okungukuthi i-US Food. kanye neDrug Administration) ngoMeyi 29 egunyaza amaphilisi e-bys10 ukuthi asetshenziswe ezivivinyweni zomtholampilo zokwelashwa kwezimila eziqinile ezithuthukisiwe ngokuhlangana kwe-RET noma ukuguqulwa.I-Baiyunshan Pharmaceutical General Factory ihlela ukwenza uhlolo lomtholampilo oluvulekile, olumaphakathi nesigaba I somuthi omusha ngezinkomba ezingenhla lapho izimo zihlangabezwana nazo maduze nje.

5.Imakethe ye-ejenti yokuqhathanisa iyakhula futhi.I-Kelun pharmaceutical iwine umuthi wokulingisa wokuqala kanye ne-Hengrui ukuya olwandle.Ngokusho kwedatha ye-Intranet, ngo-2021, ukuthengiswa kwe-ejenti ehlukile yesikhungo sezikhungo zezokwelapha zomphakathi e-China kweqa ama-yuan ayizigidi eziyizinkulungwane ezingu-17, okuwukunyuka konyaka ngo-13.05%;IHengrui pharmaceutical, General Electric pharmaceutical kanye neYangtze River Pharmaceutical ikleliswe phakathi kwezintathu eziphezulu;Inani lokuthengisa lemikhiqizo emihlanu lidlule i-yuan eyibhiliyoni, liholwa umjovo we-iodixanol.Njengamanje, izinhlobo eziyi-10 zama-agent wokuqhathanisa (izicaciso ezingama-40) zihloliwe, futhi iodophor ihlangabezane nemibandela yokuqoqwa endaweni eyodwa;Izinhlobo eziyi-12 zama-ejenti wokuqhathanisa (izicaciso zemikhiqizo engama-23) zisemakethe ukuze zibuyekezwe, futhi i-Beite pharmaceutical ingeyokuqala ukuzilingisa.

6.Ngomhla ziyisi-7 kuJuni, inkampani yezemithi i-Huiyu yamemezela ukuthi umjovo we-prosafel ephethwe yi-Seacross pharmaceuticals' ithole imvume yokubhalisa e-UK, okwenza kwaba ibhizinisi lokuqala ukuthola imvume yomuthi ojwayelekile e-UK.Kusukela kulo nyaka, imikhiqizo yomjovo we-Huiyu ivunyelwe ekhaya naphesheya.

7.Kuzovunywa ukulingisa kokuqala okungu-200!Imikhiqizo eshisayo yokulingisa yezinkampani ezinkulu yadalulwa.

Eminyakeni yakamuva, imithi yokuqala ejwayelekile iye yakhuthazwa ezingeni likazwelonke.Ngenkathi isabalalisa ngenkuthalo imithi emisha, izinkampani ezihamba phambili zemithi ezinezinga eliphezulu le-R & D nazo ziwusheshise umsebenzi “wokulingisa”.Kusukela ngo-2018, kube nemikhiqizo engaba ngu-200 efakwe isicelo sokulingisa futhi esabuyekezwa, futhi akukho mvume yasekhaya etholiwe yemikhiqizo efanayo.Kulindeleke ukuthi zigunyazwe ukufakwa ohlwini ngemuva kuka-2022, ngokushisa okuphezulu kwezimakethe eziyizinkulungwane ezingamakhulu amahlanu.

8.I-Humanwell ikhombisa amandla ayo!Imithi emisha yesigaba 20 kanye nemishanguzo emisha eyi-18 ethuthukisiwe iyashisa.

Eminyakeni yakamuva, i-humanwell pharmaceutical, umholi we-anesthesia kanye ne-sedation, iye yathuthukisa ngokuqhubekayo futhi yahlanganisa ukuncintisana kwayo okuyinhloko ngokusebenzisa "ukugxila, ukusungula izinto ezintsha kanye nokwenza amazwe ngamazwe".Muva nje, inkampani imemezele ukuthi izosebenzisa ngaphezu kwe-1.6 billion yuan ukuthenga impahla yendawo ukuze ihlanganise izinsiza zangaphakathi futhi yandise amakhono ayo.Phakathi kwazo, izimpahla zezakhiwo ezithengwe isikhungo socwaningo nentuthuko yezidakamizwa zizosetshenziswa njengesisekelo se-biomedical “sokuhweba ngobuningi nokusungula izinto” ukuze kukhuliswe isakhiwo sokusungula.Engxenyeni yokuqala ka-2022, inkampani inezinye izidakamizwa ezimbili zesigaba 1 ezigunyazwe ukusetshenziswa emtholampilo, futhi umuthi wokuqala othuthukisiwe uphuthuma emakethe.Ukulingisa kokuqala kwamaphilisi ezidakamizwa zezingane ze-chlorbazam nakho kudonse ukunaka okukhulu.Ngaphezu kwalokho, imikhiqizo emithathu emikhulu isizohlangabezana neqoqo lesikhombisa lokutholwa kukazwelonke.

9.Zhengda libalele!Izidakamizwa ezintsha zekilasi loku-1 nezingu-9 zokulingisa zokuqala.

Muva nje, umugqa womkhiqizo we-Zhengda Tianqing wezokwelapha wenze inqubekelaphambili entsha: ukukhiqizwa kwe-tq-b3101 capsule, isidakamizwa esisha se-anti-tumor sekilasi 1, kubikwe ithebhulethi yesithathu yasekhaya ye-sophopovir, kanye nomjovo we-tqc2938, isigaba esisha 1. Isidakamizwa esilwa nesifuba somoya, sagunyazwa ukuthi sisetshenziswe emtholampilo Njengamanje, i-Zhengda Tianqing Pharmaceutical Co., Ltd. inemithi emisha engama-73 (imithi emisha engama-58 ekilasi 1) esesigabeni sokusetshenziswa emtholampilo noma ngaphezulu, kuyo imithi emisha engu-14 (emisha yeklasi 1 izidakamizwa) zisesigabeni sesi-III noma ngaphezulu, futhi ukufakwa kuhlu kulindeleke;Mayelana nemithi ejwayelekile, izinhlobo ezingama-54 sezihloliwe (ezingu-21 ezokuqala), ziyi-8 izidakamizwa ezifakiwe eqoqweni lesikhombisa lokuthengwa endaweni eyodwa, kanti ezingu-15 ezisanda kubhaliswa nezimenyezelwe zisabuyekezwa, eziyi-9 kuzo azikagunyazwa ukuthi zisetshenziswe. okokuqala (kuhlanganise nekhophi yokuqala yefomu lomthamo).

I-JinDun Medicalinokubambisana kocwaningo lwesayensi yesikhathi eside kanye nokuxhunyelelwa kwezobuchwepheshe namanyuvesi aseShayina.Ngezinsiza zezokwelapha ezicebile ze-Jiangsu, inobudlelwano besikhathi eside bokuhwebelana ne-India, i-Southeast Asia, iNingizimu Korea, iJapan nezinye izimakethe.Iphinde inikeze izinsizakalo zemakethe nezokuthengisa kuyo yonke inqubo kusukela ku-API yomkhiqizo omaphakathi kuya oqediwe.Sebenzisa izinsiza eziqoqiwe ze-Yangshi Chemical kumakhemikhali e-fluorine ukuze unikezeizinsiza ezikhethekile zokwenza amakhemikhalikubalingani.Nikeza inqubo emisha kanye nezinsizakalo zocwaningo lokungcola ukuze uqondise amakhasimende.